Olaparib, a new hope for ovarian cancer

被引：0
|
作者：
Samoon, Zarka [1 ]
Jabbar, Adnan Abdul [1 ]
机构：
[1] Aga Khan Univ Hosp, Dept Oncol, Karachi, Pakistan
来源：
INDIAN JOURNAL OF CANCER | 2020年 / 57卷 / 03期
关键词：
MAINTENANCE THERAPY; PHASE-2; PARP;
D O I：
10.4103/ijc.IJC_1_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：346 / 347
页数：2
相关论文
共 50 条
  • [21] A source of hope for platinum-resistant ovarian cancer?
    Blagden, Sarah P.
    Nicum, Shibani
    LANCET, 2021, 397 (10271) : 254 - 256
  • [22] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation
    Stewart, James
    George, Angela
    Banerjee, Susana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 947 - 958
  • [23] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Nicum, Shibani
    Mcgregor, Naomi
    Austin, Rachel
    Collins, Linda
    Dutton, Susan
    Mcneish, Iain
    Glasspool, Rosalind
    Hall, Marcia
    Roux, Rene
    Michael, Agnieszka
    Clamp, Andrew
    Jayson, Gordon
    Kristeleit, Rebecca
    Banerjee, Susana
    Mansouri, Anita
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 941 - 950
  • [24] Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
    Rogmans, Christoph
    Dittrich, Jan
    Hamm, Emily
    Weimer, Joerg Paul
    Holthaus, David
    Arnold, Norbert
    Floerkemeier, Inken
    Maass, Nicolai
    Jansen, Peer
    Dempfle, Astrid
    Bauerschlag, Dirk O.
    Hedemann, Nina
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [25] Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer
    Moore, Kathleen N.
    Monk, Bradley J.
    ONCOLOGIST, 2016, 21 (08) : 954 - 963
  • [26] Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
    Joanna Baum
    Daniel Zickler
    Juliane Bolbrinker
    Rolf Richter
    Elena Ioana Braicu
    Jacek Grabowski
    Jalid Sehouli
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 325 - 330
  • [27] Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer
    Dockery, Lauren E.
    Tew, William P.
    Ding, Kai
    Moore, Kathleen N.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (03) : 509 - 513
  • [28] Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
    Baum, Joanna
    Zickler, Daniel
    Bolbrinker, Juliane
    Richter, Rolf
    Braicu, Elena Ioana
    Grabowski, Jacek
    Sehouli, Jalid
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (04) : 325 - 330
  • [29] Olaparib for ovarian cancer: a single-institution, multi-site qualitative study
    Martin, Nichole A.
    Hanna, Mina
    Ehret, Christopher
    Asiedu, Gladys
    Jatoi, Aminah
    SUPPORTIVE CARE IN CANCER, 2022, 30 (06) : 4807 - 4812
  • [30] Olaparib for ovarian cancer: a single-institution, multi-site qualitative study
    Nichole A. Martin
    Mina Hanna
    Christopher Ehret
    Gladys Asiedu
    Aminah Jatoi
    Supportive Care in Cancer, 2022, 30 : 4807 - 4812
12345